US equities |
MU $910.55 ▼-0.39% NVDA $217.23 ▼-1.84% SNDK $1,337.20 ▼-4.71% SPCX $146.60 ▼-3.65% AMD $548.77 ▼-3.86% INTC $94.06 ▼-4.14% AAPL $344.50 ▲+0.45% TSM $419.22 ▼-2.51%
FinancialContent

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

34.57 +0.67 (+1.98%)
Delayed Quote Updated: 1:21 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Analyst Ratings for Xenon Pharmaceuticals ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗
 
Via Benzinga
News headline image
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Where Xenon Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Analyst Sees This Epilepsy Player As 'M&A Sweet Spot' ↗
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗
 
Via Benzinga
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Xenon Pharmaceuticals ↗
Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022 ↗
 
Via Benzinga
News headline image
Analyst Ratings for Xenon Pharmaceuticals ↗
Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
4 Analysts Have This to Say About Xenon Pharmaceuticals ↗
  Within the last quarter, Xenon Pharmaceuticals (NASDAQ:XENE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing ↗
Biotech stocks were hammered Wednesday, including several that had good news. 
Via Investor's Business Daily
News headline image
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 8, 2022 ↗
Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million. 
Via Benzinga
News headline image
Earnings Preview: Xenon Pharmaceuticals ↗
Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Xenon... 
Via Benzinga
News headline image
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Launch of XEN1101 Phase 3 Program with Initiation of X-TOLE2 Clinical Trial in Patients with Focal Onset Seizures
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Hurry! 7 Pitiful Nasdaq Stocks to Sell Before 2022 Ends. ↗
As the Fed continues to tighten the market, consider putting these seven on your list of overvalued Nasdaq stocks to sell before 2022 ends. 
Via InvestorPlace
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Swing Trading Stock Watchlist For The Week Of Sept. 6 ↗
The overall stock market health is poor. I created a watchlist this week mainly to see how many stocks were forming quality contraction or cup-and-handle patterns. Let's take a look. 
Via Talk Markets
News headline image
Xenon Pharmaceuticals May Have A Blockbuster Drug In Store, BofA Says ↗
Xenon Pharmaceuticals Inc’s (NASDAQ: XENE) epilepsy candidate, XEN1101, is currently in phase III trials and “looks poised to be a blockbuster,” according to BofA Securities. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Xenon Pharmaceuticals ↗
  Analysts have provided the following ratings for Xenon Pharmaceuticals (NASDAQ:XENE) within the last quarter: 
Via Benzinga
News headline image
Xenon Pharmaceuticals: Q2 Earnings Insights ↗
  Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For August 9, 2022 ↗
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
News headline image
Earnings Outlook For Xenon Pharmaceuticals ↗
  Xenon Pharmaceuticals (NASDAQ:XENE) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >